Biotherapy monitoring, a major area of interest at the European Crohn's and Colitis Organisation (ECCO) Congress
Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study
![Targeting Disease Progression in Crohn's Disease: Fighting an Unrelenting Enemy - European Medical Journal Targeting Disease Progression in Crohn's Disease: Fighting an Unrelenting Enemy - European Medical Journal](https://emj.emg-health.com/wp-content/uploads/sites/2/2018/01/New-Website-Photographs-.8.jpg)
Targeting Disease Progression in Crohn's Disease: Fighting an Unrelenting Enemy - European Medical Journal
![Data presented at ECCO congress supports switching from Remicade® to biosimilar infliximab - Hospital Pharmacy EuropeHospital Pharmacy Europe Data presented at ECCO congress supports switching from Remicade® to biosimilar infliximab - Hospital Pharmacy EuropeHospital Pharmacy Europe](https://hospitalpharmacyeurope.com/wp-content/uploads/2017/04/Gastroenterology-1.jpg)
Data presented at ECCO congress supports switching from Remicade® to biosimilar infliximab - Hospital Pharmacy EuropeHospital Pharmacy Europe
![Galapagos Reports Positive Phase 2 Trial Data of Crohn's Disease Drug Filgotinib at ECCO Congress - IBD News Today Galapagos Reports Positive Phase 2 Trial Data of Crohn's Disease Drug Filgotinib at ECCO Congress - IBD News Today](https://ibdnewstoday.com/wp-content/uploads/2016/03/shutterstock_392092564-375x480@2x.jpg)